Barvarian Nordic provides update on randomized Phase III trial of Prostvac VF

According to a media release issued earlier today by Barvarian Nordic, the company expects to complete enrollment of patients in the randomized, double-blind, placebo-controlled, multi-center, Phase III PROSPECT trial of Prostvac VF within the next 12 months. … READ MORE …

Better identification of potentially good responders to prostate cancer immunotherapy

A paper just published in Clinical Cancer Research has suggested that — at least for one immunotherapeutic agent (“vaccine”) in development for the treatment of advanced prostate cancer — it may be possible to define a subgroup of men who are more likely to respond well to treatment than others. … READ MORE …

Why a specialized smallpox vaccine may affect future prostate cancer therapy

A decision (or the lack of it) by the US federal government may imperil viability of the Swedish company known as Barvarian Nordic — and the development of Prostvac VF, now in development for treatment of advanced prostate cancer. … READ MORE …

Other prostate cancer news: Wednesday, December 8, 2010

Other prostate cancer news out today includes:

  • An article in the Wall Street Journal about the financial motives behind intensity-modulated radiation therapy (IMRT)
  • Approval from the FDA for a Phase III pivotal trial of PROSTVAC-VF … READ MORE …

A Phase III clinical trial of PROSTVAC-VF may be in the offing

According to a story on ScienceDaily today, investigators are continuing to plan for a Phase III clinical trial of PROSTVAC-VF — a poxvirus-based prostate cancer “vaccine” — in men with castration-resistant prostate cancer (CRPC). … READ MORE …

ASCO commentary and update no. 1

On Saturday there were two major prostate cancer sessions and additional poster sessions that included prostate cancer-related material at the annual meeting of the American Society for Clinical Oncology. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,134 other followers